The weight-loss jab is here. Your gym’s biggest opportunity just walked in.

On 20 March 2026, something quietly changed India's fitness business. The patent on semaglutide, the drug behind Ozempic and Wegovy, expired. More than 40 Indian drugmakers lined up with their own versions, and over 50 brand names are expected this year. The price fell off a cliff. Branded semaglutide cost about ₹10,850 to ₹16,400 a month. Generics are launching 50–60% cheaper, and one injectable starts at ₹1,290 a month. If you run a gym, this matters more than any new machine you will buy this year. Here's why. The people who will use it are already your audience India's own ICMR-INDIAB study counted about 254 million adults with generalised obesity and 351 million with abdominal obesity. That is a huge group of people who have tried diets, tried walking, maybe tried your gym, and given up. A drug that finally moves the scale will bring many of them back to thinking about their health. The question is whether they think of you. The catch nobody puts on the poster These medicines work. But a January 2026 evidence review by Les Mills and ukactive found that 20–50% of the weight lost on GLP-1 drugs can be muscle and bone, not fat. One research discussion compared 68–72 weeks of treatment to roughly 20 years of normal age-related muscle loss. It gets worse when people stop. The same review found weight comes back about four times faster after stopping the medicine than after other ways of losing weight. And here's the surprise. You might expect people to feel lighter and move more. A study of 753 adults on GLP-1 drugs, using Fitbit data from the US All of Us research programme, found the opposite: • Daily steps dropped from 5,047 to 4,487. • Moderate-to-vigorous activity fell from 28 to 22 minutes a day. As the lead researcher, Dr Sajana Maharjan, put it: "Exercise cannot be optional for people taking these medications." Strength training is the missing half of the prescription The fix is not complicated. It is what good gyms already do. The Les Mills and ukactive review recommends strength training two to three times a week, plus 150 minutes of moderate activity. People who keep exercising during treatment hold on to more lean mass and more of their fat loss after they stop the drug. The world's exercise scientists agree. In the American College of Sports Medicine's survey of 2,000 fitness professionals, "Exercise for weight management" rose to number 3 of the top trends for 2026, its highest ever. ACSM renamed the trend specifically to include people on medications like GLP-1s. What this means for your gym Think of a member on a GLP-1 drug as a new kind of member. They are motivated, often new to lifting, sometimes low on energy, and eating less than usual. Here's how to serve them well: 1. Lead with muscle, not calories. Your message is not "burn fat". It is "keep your strength while the medicine does its job". 2. Start gentle and progressive. Two or three short full-body strength sessions a week beat one exhausting class. 3. Talk about protein. Appetite drops on these drugs. A coach who reminds members to eat enough protein is giving real value. (Leave detailed diet plans to qualified nutritionists and doctors.) 4. Build doctor relationships. Endocrinologists and diabetes clinics in your city need somewhere safe to send patients. A simple referral partnership can fill your morning slots. 5. Plan for the day they stop. The months after stopping the drug are when weight returns fastest. A "life after the jab" programme keeps members, and keeps their results. The bottom line Cheap GLP-1s will not empty gyms. If anything, they will send a wave of new people looking for help to stay strong. The gyms that win will be the ones that understand what these members are going through, and talk to them like a coach, not a salesperson. Note: GLP-1 medicines are prescription drugs. Anyone considering them should speak to a qualified doctor. This article is about how gyms can support members, not medical advice. Sources Business Today semaglutide article - https://www.businesstoday.in/amp/industry/pharma/story/indias-weight-loss-drug-moment-what-happens-when-semaglutide-goes-generic-521612-2026-03-20 Athletech News (GLP-1 users exercising less) - https://athletechnews.com/people-who-use-glp-1s-are-exercising-less-study-finds/ Les Mills GLP-1 report - https://www.lesmills.com/nordic/articles/glp1-report Club Solutions article - https://clubsolutionsmagazine.com/2026/03/exercise-is-the-other-half-of-the-glp-1-equation-heres-why/ ACSM 2026 trends - https://acsm.org/top-fitness-trends-2026